Astrazeneca (AZN) Net Income towards Common Stockholders Growth (3y) (2012 - 2026)
Astrazeneca (AZN) Net Income towards Common Stockholders Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.47% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 39.28% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -60.22% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 11.31% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 19.87% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -129.59% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -28.09% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -34.02% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -36.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.31% |
| Mar 31, 2026 | 12.19% |
| Dec 31, 2025 | 17.40% |
| Sep 30, 2025 | 16.23% |
| Jun 30, 2025 | 104.77% |
| Mar 31, 2025 | 114.86% |
| Dec 31, 2024 | 58.85% |
| Sep 30, 2024 | 49.47% |
| Jun 30, 2024 | 17.49% |
| Mar 31, 2024 | 20.89% |
| Dec 31, 2023 | 6.17% |
| Sep 30, 2023 | 8.12% |
| Jun 30, 2023 | 28.65% |
| Mar 31, 2023 | 55.34% |
| Dec 31, 2022 | 39.64% |
| Sep 30, 2022 | 93.45% |
| Jun 30, 2022 | 3.58% |
| Mar 31, 2022 | -11.94% |
| Sep 30, 2021 | -100.10% |
| Jun 30, 2021 | 63.69% |